# Mosaic Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mosaic-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.mosaic-tx.com
- Total disclosed funding: $28M
- Latest round: Series A (Apr 4, 2023)
- Investors on record: 2

## About

Based in the UK, and founded in 2020, Mosaic Therapeutics Ltd. operates as a biotechnology company that reshapes the boundaries of machine learning and experimental medicine in order to develop medicines for patients. In April, Mosaic Therapeutics Ltd. raised USD 28 million in series A funding from Cambridge Innovation Capital and Syncona Limited.

Mosaic Therapeutics Ltd. is an operator of an oncology therapeutics company aimed at cancers with significant unmet needs. Using next-generation tumor systems and advanced genomic technologies, the company uses artificial intelligence to prioritize key anti-cancer targets and genetically identify those patient groups most likely to respond to treatments developed against those targets, allowing patients to treat cancers based on their tissue of origin.

The company plans to use the April funding to further develop its oncology treatments for biomarker-selected individuals, boost hiring initiatives, and expand its experimental biology, computational, and senior leadership teams.

## Funding rounds

- Series A, Apr 4, 2023, $28M — Syncona, Cambridge Innovation Capital

## Investors

- Syncona (https://capitalatlas.ai/funds/syncona) — Series A
- Cambridge Innovation Capital (https://capitalatlas.ai/funds/cambridge-innovation-capital) — Series A